HCQ has demonstrated in-vitro activity against SARS-CoV-2 and shown to be clinically beneficial in several small single-centre studies with significant limitations. The Health Ministry on Saturday recommended the use of antiviral drug in the moderate stage of COVID-19 while backtracking from its earlier stance on hydroxychloroquine, saying the anti-malarial drug should be used in the early course of the disease …
)